Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis

被引：0
|
作者：
Afach, Sivem [1 ]
Le Cleach, Laurence [1 ,2 ]
Sbidian, Emilie [1 ,2 ]
机构：
[1] Univ Paris Est Creteil, UPEC EpiDermE EA, Creteil, France
[2] UPEC, Hop Univ Henri Mondor, AP HP, Dept Dermatol, Creteil, France
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
32102
引用
收藏
页码：AB103 / AB103
页数：1
相关论文
共 50 条
  • [1] Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis
    Afach, S.
    Le Cleach, L.
    Sbidian, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 15 - 15
  • [2] Placebo Response in Moderate-to-Severe Psoriasis: Prevalence Meta-Analysis of Randomized Controlled Trials
    Afach, Sivem
    Le, Laurence
    Sbidian, Emilie
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (06) : 1101 - 1104
  • [3] A NETWORK META-ANALYSIS OF RANDOMIZED, CONTROLLED TRIALS OF USTEKINUMAB AND ADALIMUMAB FOR MODERATE-TO-SEVERE PSORIASIS
    Odom, D.
    Brogan, A.
    Talbird, S. E.
    Schenkel, B.
    VALUE IN HEALTH, 2013, 16 (03) : A112 - A112
  • [4] Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Toth, Otavio A. S.
    Meldola, Patrick F.
    Machado, Pablo G.
    Chiarelli, Gabriel F. C.
    Schnorrenberger, Erick
    Kracik, Jose L. S.
    de Carvalho, Caio C.
    Guzatti, Joao V. L.
    Mease, Philip J.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (02) : 67 - 73
  • [5] Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Papp, K. A.
    Kimball, A. B.
    Gooderham, M.
    Tyring, S. K.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitz, N.
    Green, S.
    La Rosa, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (03) : 615 - 622
  • [6] Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
    Schmitt, J.
    Rosumeck, S.
    Thomaschewski, G.
    Sporbeck, B.
    Haufe, E.
    Nast, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 274 - 303
  • [7] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials
    Blauvelt, Andrew
    Reich, Kristian
    Drew, Janice
    Peterson, Luke
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
  • [8] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Lebwohl, M.
    Burge, D.
    Arendt, C.
    Peterson, L.
    Drew, J.
    Rolleri, R.
    Gottlieb, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E249 - E250
  • [9] A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis
    No, Daniel J.
    Amin, Mina
    Bhutani, Tina
    Wu, Jashin J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (05) : 467 - 474
  • [10] Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28
    Papp, K. A.
    Reich, K.
    Blauvelt, A.
    Kimball, A. B.
    Gooderham, M.
    Tyring, S. K.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitz, N.
    Green, S.
    La Rosa, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (06) : 1098 - 1106
12345